Research & Clinical Trials
If you would like to learn more about participating in a research study or clinical trial, you may find our list of frequently asked questions (FAQ) helpful. If you have a question not addressed on our FAQ list, you may email us at research@memorialhermann.org.
 = Open to Enrollment |
|
|
| Principal Investigator: Maria Matuszczak, M.D. |
This study is comparing the safety and efficacy of the Truview laryngoscope and the Macintosh laryngoscope blade in pediatric patients.
Principal Investigator: Miguel Escobar, M.D.The safety of long-term use of the FDA-approved drug alphanate is being studied in individuals with severe hemophilia A.
|
|
| Principal Investigator: Gloria Heresi, M.D. |
This study is assessing the safety, effectiveness and pharmacokinetics (interactions of a drug and the body in terms of its absorption, distribution, metabolism and excretion) of the drug daptomycin in pediatric patients with complicated skin and skin structure infections (cSSSI) caused by gram-positive pathogens. cSSSIs require treatment with intravenous antibiotics.
|
|
| Principal Investigator: Deborah Brown, M.D. |
The primary objective of this study is to demonstrate that ReFacto AF given as a preventive reduces annualized bleeding rates (ABRs) in children with hemophilia A, relative to on-demand therapy.
Principal Investigator: Stacey Moore-Olufemi, M.D.
Researchers are examining the transcriptional profile and methylation patterns of genes expressed in the intestine of pre-term infants with and without necrotizing enterocolitis (NEC). The study is attempting to identify the expression of genes in normal versus diseased intestine so that a potential animal model can be developed to study genes or pathways that contribute to NEC.
Principal Investigator: Megan Ullman, M.A., M.P.H.
This Phase V study is examining the long-term cost and burden of hemophilia, including the impact of joint disease, quality of life and economic impact on patients. Researchers hope that an understanding of various approaches to treatment, outcomes of care and differences in the cost of illness will assist in policy decisions that ensure adequate care with the best outcomes for chronically ill patients.
|
|
| Principal Investigator: Robert Yetman, M.D. |
Researchers are collecting blood samples from healthy children to see if a new blood thinner, currently being studied in adults, can also be used in children. The drug, apixaban, may help prevent or treat blood clots.
|
|
| Principal Investigator: Kevin Lally, M.D. |
Researchers are creating a DNA and tissue bank repository devoted to the study of congenital diaphragmatic hernia (CDH). Material collected in the repository will be stored and used in molecular studies to identify and describe chromosomal regions and specific genes that cause CDH.
|
|
| Principal Investigator: Kevin Lally, M.D. |
Researchers aim to create a DNA and tissue bank repository devoted to the study of tracheal/esophageal anomalies and VACTERL association (defects in the spine, anus, heart, kidneys and limbs).
Principal Investigator: Galit Holzmann-Pazgal, M.D.
Investigators are testing MRSA strains acquired during hospitalizations from January 1, 2006, through December 31, 2007, in the microbiology laboratory.
|
|
| Principal Investigator: Mark Sanders, M.D. |
Researchers seek to clarify the role of multiple- versus single-pathogen infections in bronchiolitis and to determine the value of PCR testing for the cause of the infections. The secondary objective is to create high-risk and low-risk clinical rules to predict reliably those children with bronchiolitis who require continuous positive airway pressure (CPAP) or intubation and those who do not require intensive care.
Principal Investigator: Jon Tyson, M.D.
Patients who were enrolled in a randomized trial of hypothermia (cooling of the body) conducted at Children’s Memorial Hermann Hospital and LBJ General Hospital from January 2000 to May 2003 are being followed over a 6- to 7-year time period. Those who were treated with hypothermia had better initial outcomes; investigators are following up to see if significant differences exist at school age.